Effects of propionyl-carnitine in patients with type 2 diabetes and peripheral vascular disease: results of a pilot trial

Drugs in R&D
Giovanni RagozzinoPasquale Federico

Abstract

To assess the efficacy of propionyl-carnitine (PC) in patients with type 2 diabetes and peripheral arterial disease (PAD). This was an open pharmacodynamic study. Twenty-four obese patients with type 2 diabetes and PAD (stage IIb) were enrolled in the study. After an initial run-in period of 7 days on a low-calorie diet (1600 +/- 150 kcal/day), patients received intravenous PC (600mg in 100mL saline solution Na/K 0.9%) twice daily for 10 days (T1). Treatment with PC produced statistically significant increases in maximal walking distance (30%; p < 0.05) and initial claudication distance (15%; p < 0.05) in 15 and eight patients, respectively. In addition, a decrease in dosage of oral antihyperglycaemic agents was observed in 21 patients at T1. No PC-related adverse effects were reported. This study showed that acute intravenous administration of PC in patients with type 2 diabetes with PAD improved PAD-related symptoms as well as glycaemic control.

References

Jul 1, 1979·Physiological Reviews·B ChanceA Boveris
Dec 1, 1979·Diabetes·S M Genuth, C L Hoppel
Feb 1, 1991·Cardiovascular Drugs and Therapy·V W van Hinsbergh, M A Scheffer
Jan 1, 1990·Journal of Clinical Epidemiology·W R HiattR F Hamman
Oct 1, 1986·Journal of Applied Physiology·J I CarlinR Hodach
Jun 1, 1987·Journal of Applied Physiology·W R HiattE P Brass
Oct 1, 1983·Physiological Reviews·J Bremer
Sep 15, 1980·The Biochemical Journal·E P Brass, C L Hoppel
Jan 1, 1997·Vascular Medicine·W R Hiatt
Oct 31, 1998·European Journal of Pharmacology·R TeradaN Hotta
Apr 18, 2001·European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery·H AkarF Kolbakir
Apr 18, 2001·The Journal of Physiology·P M Taylor

❮ Previous
Next ❯

Citations

Feb 16, 2012·Current Opinion in Gastroenterology·Mariano Malaguarnera
Feb 13, 2020·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·UNKNOWN ALSUNTANGLED GROUP
Apr 23, 2010·Endocrine Research·Fatih KiliçliIlkay Cakir
Nov 1, 2008·Expert Review of Endocrinology & Metabolism·Carani V Anuradha
Oct 16, 2009·Expert Opinion on Pharmacotherapy·G M Andreozzi

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.